INTRODUCTION
============

Breast cancer has one of the fastest growing incidence rates around the world and a relatively high incidence rate in high-income countries \[[@B1]\]. Worldwide, according to the GLOBOCAN 2012 database, breast cancer accounts for 25.5% of all cancers in women \[[@B1]\]. Following thyroid cancer, breast cancer is the second most frequent among cancer incidences in Korean women \[[@B2]\]. Growth and metastasis of breast cancer are a result of both environmental and genetic factors \[[@B3]\]. In such circumstances, identifying genetic hallmarks related to the growth and metastasis of breast cancer can be seen as an important first step when pursuing potential breast cancer treatment approaches.

The high mobility group box 1 (HMGB1) protein is involved in DNA translation and replication \[[@B4]\]. It also has a role in apoptosis \[[@B5]\] and immune responses \[[@B6]\] because it can act as a ligand for the receptor for advanced glycation end products (RAGE) \[[@B7]\], various Toll-like receptors (TLR2, TLR4, and TLR9) \[[@B8]\], and the triggering receptor expressed on myeloid cells 1 \[[@B9]\]. Two previous meta-analyses focused on RAGE, not HMGB1, and mainly investigated associations with risks for various types of cancers excluding breast cancer \[[@B10][@B11]\]. Recent research on the HMGB1/RAGE pathway done in a Chinese Han population showed a significant association between polymorphisms of the *RAGE* gene and breast cancer risk; however, there are few studies on the effects of *HMGB1* and its related genes on breast cancer prognosis \[[@B12]\]. With the current increase in breast cancer incidence, it is important to study the effects of these genes on breast cancer prognosis in Korean women.

In this study, we hypothesized that polymorphisms of *HMGB1*-related genes would be significantly associated with breast cancer prognosis. *HMGB1* and *HMGB1*-related genes were investigated, and their significant single nucleotide polymorphisms (SNPs) were extracted. The effects of those SNPs on breast cancer prognosis were assessed at both the individual and cumulative levels.

METHODS
=======

Study population
----------------

The Seoul Breast Cancer Study (SEBCS) is a multicenter-based case-control study conducted in Seoul, Korea. Further details have been previously described elsewhere \[[@B13]\]. A total of 4,040 patients with histologically confirmed breast cancer were recruited from the Seoul National University Hospital (SNUH), Asan Medical Center (AMC), and National Cancer Center (NCC) from 2001 to 2007. Participant information was collected through questionnaire-based interviews and medical charts reviews \[[@B14]\]. Each patient was treated with chemotherapy, hormone therapy, and radiotherapy according to their estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) status and TNM stage. Among those subjects, 2,342 breast cancer patients with sufficient DNA samples and successful genotyping were selected. We excluded participants who had a previous history of breast or other cancers before recruitment (n=119), were diagnosed with benign breast diseases (n=41) or had no clinicopathological information (n=26). For the survival analysis, subjects who were lost to follow-up (n=117) were excluded; thus, a total of 2,027 subjects were included in this analysis. All subjects in the SEBCS provided written informed consent to participate, and the study design was approved by the Institutional Review Board of Seoul National University Hospital (IRB number: H-0503-144-004).

Genotyping
----------

Peripheral blood samples from all participants were used for standard genotyping \[[@B13]\]. The *HMGB1* gene and five of its binding receptor genes were selected as candidate genes \[[@B15]\]. Additionally, matrix metalloproteinase 2 (*MMP2*) and *MMP9*, which are reportedly involved in the HMGB1/RAGE pathway \[[@B16]\], were selected resulting in eight candidate genes included in this study. One hundred sixteen SNPs were extracted from these eight genes with the Affymetrix Genome-Wide Human SNP Array 6.0 chip (Thermo Fisher Scientific Inc., Santa Clara, USA) \[[@B13]\]. The SNP searching range was 20 kb upstream of the first transcriptional position of the candidate gene to 20 kb downstream of the last exon. The exact location of each SNP was determined based on information in the University of California, Santa Cruz\'s genome browser \[[@B17]\]. If SNPs were correlated in the same candidate gene and had a linkage disequilibrium (LD) (r^2^\>0.3), the SNPs with the lowest *p*-values were selected among the correlated SNPs.

Statistical methods
-------------------

Disease-free survival (DFS) is the period from the date of breast cancer surgery until the confirmed date for recurrence, including local and distant metastasis, death, or the last follow-up observation date. Overall survival (OS) is the period from the date of diagnosis of breast cancer until the last follow-up observation date, or the confirmed date of patient death. Detailed follow-up information about was described in a previous study \[[@B18]\]. Among the 2,027 patients enrolled in this study, there were 248 patients with a DFS event and 134 patients with an OS event.

Demographic patient data included age (\<40, 40--49, 50--59, and ≥60 years), recruiting site (SNU, AMC, and NCC), education (less than high school, high school, and college or higher), family history of breast cancer (no and yes), body mass index (BMI; \<18.5, 18.5--22.9, 23.0--24.9, and ≥25.0), menopausal (premenopausal and postmenopausal), age at menarche (\<15 and ≥15 years), age at menopause among postmenopausal women (\<49 and ≥49 years), parity (parous and nulliparous), number of children among parous women (1, 2, and ≥3), and duration of breastfeeding among parous women (never, \<18 and ≥18 months). Clinicopathological data including TNM stage (0--I, II, and ≥III), ER (positive and negative), PR (positive and negative), HER2 (positive and negative) tumor subtype (hormone receptor \[HR\]+HER2−, HR+HER2+, HR−HER2+, and HR−HER2−), histological grade (I, II, and III), and treatment information including adjuvant chemotherapy (yes and no), adjuvant hormone therapy (yes and no), and adjuvant radiotherapy (yes and no). The clinicopathological and demographic data of both the DFS and OS groups were assessed with the log-rank test and the multivariate Cox proportional hazards model. Based on the results of the demographic and clinicopathological analyses, the multivariate Cox proportional hazards model was adjusted for age, TNM stage, and tumor subtype that were significantly associated with both DFS and OS. The multivariate model was used to estimate the breast cancer hazard ratio and 95% confidence interval (CI) of each SNP. For both the DFS and OS groups, additive, codominant, and dominant models were used in our comparative analysis.

The effects of the SNPs on breast cancer prognosis were assessed at the cumulative level by assessing polygenic risk scores. To use the polygenic risk score model, the following equation was adapted \[[@B19]\]: $$x = {\sum\limits_{i = 1}^{m}{\left( {n_{i} - e_{i}} \right)b_{i}}}$$

where *m* is the total number of SNPs included in the risk score; *n*~*i*~ is the number of risk-alleles for the *i*th SNP; *e*~*i*~ is the mean number of risk alleles for the ith SNP among the nonevent group, and *b*~*i*~ is the log of the per-allele hazard ratio for the ith SNP. With this model, the risk allele counts of the patients\' significant SNPs were tallied. Each count was weighted by multiplying the estimated hazard ratio at each individual level of the SNP \[[@B19]\]. The weighted values were summed to calculate the polygenic risk score for each patient. Both the DFS and OS data were analyzed separately. If any genotyping information was absent among the SNPs analyzed, those patients were excluded from the analysis. Thus, among the 2,027 patients in our study, 2,009 patients were included in the DFS model analysis and 2,004 patients in the OS model analysis. After sorting by polygenic risk score, the patients were categorized into tertiles. By using the multivariate Cox proportional hazards model, the hazard ratio and 95% CI were calculated for the second tertile and third tertile based on the first tertile, which had the lowest polygenic risk score as the reference value. Harrell\'s C index was calculated to evaluate the predictive accuracy of each model. The basic model consisted of age, TNM stage and tumor subtype, and genetic models were made by adding SNPs with significance, or polygenic risk score made from significant SNPs, to the basic model. The difference between the basic model and genetic model was compared with the Newson method \[[@B20]\]. The PLINK software version 1.07 (<http://pngu.mgh.harvard.edu/>) was used to analyze individual SNPs, and the SAS software version 9.4 (SAS Institute Inc., Cary, USA) was used to analyze the Kaplan-Meier survival curves and multivariate Cox proportional model in the polygenic risk score models. Stata/MP 12.0 software (StataCorp LP, College Station, USA) was used to calculate Harrell\'s C index.

RESULTS
=======

[Table 1](#T1){ref-type="table"} summarizes the characteristics of the 2,027 patients in this study, which includes 248 patients with a DFS event and 134 patients with an OS event. The median follow-up duration was 3.8 years (range, 2.9--4.9 years) for the DFS events group and 3.9 years (range, 3.0--4.9 years) for the OS events group. In both event type groups, TNM stage, ER status, and PR status were significantly associated with breast cancer prognosis, while there were no significant differences in age, education level, family history of breast cancer, BMI, HER2 status, menopausal status, age at menarche, age at menopause, parity, number of children, and adjuvant radiotherapy. Recruiting site was only associated with DFS events, and duration of breastfeeding and adjuvant hormone therapy were only associated with OS events. The status of adjuvant chemotherapy, hormone therapy, and radiotherapy were significantly different according to the ER and PR status and the TNM stage (data not shown).

After excluding SNPs with a high LD value (r^2^\>0.3), five SNPs were selected for further assessment ([Table 2](#T2){ref-type="table"}). [Table 3](#T3){ref-type="table"} shows the associations between the genetic variations of the *HMGB1*-related genes and breast cancer prognosis for both the DFS and OS groups. The most significant SNPs among the DFS patients were rs243867 (hazard ratio, 1.26; 95% CI, 1.05--1.50; *p*=0.015) and rs243842 (hazard ratio, 1.24; 95% CI, 1.03--1.50; *p*=0.037), both of which are SNPs of *MMP2*. Among the OS patient group, rs243842 in *MMP2* (hazard ratio, 1.33; 95% CI, 1.03--1.71; *p*=0.028), rs4145277 in *HMGB1* (hazard ratio, 1.29; 95% CI, 1.00--1.66; *p*=0.048), rs7656411 in *TLR2* (hazard ratio, 0.76; 95% CI, 0.60--0.98; *p*=0.030), and rs7045953 in *TLR4* (hazard ratio, 0.50; 95% CI, 0.29--0.84; *p*=0.009) were found to be the most significant SNPs. Additionally, the association of SNPs with breast cancer prognosis were assessed with a codominant model. Those results showed a similar tendency as that in the additive model.

[Figure 1](#F1){ref-type="fig"} shows the Kaplan-Meier survival curves, and [Table 4](#T4){ref-type="table"} presents the estimated hazard ratios by the polygenic risk score tertiles of breast cancer for the DFS and OS event type groups. In the Kaplan-Meier curve, the recurrence and mortality rate were differently distributed according to each tertile group (*p*=0.024 for DFS and *p*=0.002 for OS). Analysis of the polygenic risk scores for the DFS event group showed a hazard ratio for the third tertile of 1.72 (95% CI, 1.27--2.34) compared to the reference value of the first tertile. Within the OS event group, the hazard ratio of the third tertile was 2.75 (95% CI, 1.79--4.23) compared to the reference value of the first tertile.

Harrell\'s C index with age, TNM stage, and tumor subtype was 0.723 for DFS and 0.796 for OS. Harrell\'s C index increased when adding each significant SNP (highest Harrell\'s C index 0.731 for DFS and 0.802 for OS) and polygenic risk score (Harrell\'s C index 0.732 for DFS and 0.810 for OS), although the differences between the basic model and genetic models were not statistically significant (data not shown).

DISCUSSION
==========

The results of this study show that the SNP rs243842 of the *MMP2* gene was consistently associated with breast cancer prognosis in patients with DFS or OS events. Among the DFS patients, rs243842 and rs243867 of the *MMP2* gene showed statistically significant associations with a poor breast cancer prognosis, while among the OS patients, rs243842 in the *MMP2* gene and rs4145277 in the *HMGB1* gene were significantly associated with a poor breast cancer prognosis. In contrast, rs7656411 in *TLR2* and rs7045953 in *TLR4* were significantly associated with a good prognosis in the OS patients. Additionally, the results of our polygenic risk score model analysis for genetic polymorphisms of *HMGB1*-related genes confirmed that the hazard ratios in the DFS and OS event patients tended to increase as the risk allele count increased.

The HMGB1 protein is a damage-associated molecular pattern molecule that has an essential role in the inflammatory response \[[@B21]\]. Previous research has shown that malignant mesothelioma cells secrete HMGB1 \[[@B22][@B23]\]. Moreover, HMGB1 induces the secretion of tumor necrosis factor α by macrophages and the activation of nuclear factor-κB. These actions accelerate tumor growth by expediting cell proliferation and suppressing cell apoptosis \[[@B22][@B24]\]. In addition to HMGB1, malignant mesothelioma cells also express high levels of TLR2 and TLR4, which suggests that the HMGB1/TLR pathway may influence tumor growth and metastasis \[[@B22]\]. Considering the results of previous studies describing the functions of the *HMGB1*-related genes and the results of the present study, it can be assumed that there is an association between the increased expression of HMGB1 by rs4145277 and a poorer breast cancer prognosis. Moreover, rs7656411 and rs7045953 may reduce the expression of TLR2 and TLR4, which bind to HMGB1, and are correlated with a good breast cancer prognosis.

Further analysis shows rs243842 SNP in the *MMP2* gene was significantly associated with breast cancer prognosis in both the DFS and OS groups while rs243867 was associated with breast cancer prognosis only in the DFS group. Previous research using *in vivo* and *in vitro* models showed an increased HMGB1/RAGE level in cancer cells \[[@B15]\]. Additionally, blocking RAGE has been shown to reduce the decomposition of extracellular matrix molecules by suppressing the MMP2 activity \[[@B16]\]. Hence, the HMGB1/RAGE complex promotes growth and metastasis of cancer cells by facilitating cellular invasion. Moreover, human serum MMP2 levels have been associated with breast cancer prognosis \[[@B25]\]. To summarize, these results suggest that rs243842 and rs243867 are involved in the activation of MMP2, thus leading to a poorer breast cancer prognosis.

A limitation of this study is the absence of external validation. Additionally, the use of tagging SNPs that were selected based on the data of a Caucasian population may be a limitation. However, one of the strengths of this study is that it considered and analyzed both *HMGB1* and *HMGB1*-related genes, which have roles in cancer. Furthermore, this study shows the effects of *HMGB1* and its related genes in a large sample of female Korean breast cancer patients.

In conclusion, the results of this study and previous studies, show that there are significant associations between the *HMGB1*, *TLR2*, *TLR4*, and *MMP2* genes and the prognosis for breast cancer.
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###### Baseline characteristics and prognosis of breast cancer patients in the Seoul Breast Cancer Study

![](jbc-20-27-i001)

  Characteristic                                      All (n=2,027)   DFS event (n = 248, 12.2%)   OS event (n=134, 6.6%)                                                      
  --------------------------------------------------- --------------- ---------------------------- ------------------------ ------------ ------------ ------- ------------- -- --
  Age (yr)                                                                                         0.429                                                      0.104            
   \< 40                                              354 (17.5)      46 (18.5)                    1.08                     0.76--1.54   27 (20.2)    1.13    0.71--1.80       
   ≥ 40, \< 50                                        894 (44.1)      100 (40.3)                   1.00                     Ref          53 (40.0)    1.00    Ref              
   ≥ 50, \< 60                                        526 (26.0)      68 (27.4)                    1.19                     0.88--1.63   30 (22.4)    0.89    0.56--1.41       
   ≥ 60                                               253 (12.5)      34 (13.7)                    1.29                     0.88--1.91   24 (18.0)    1.73    1.06--2.81       
  Recruiting site                                                                                  0.002                                                      0.280            
   SNUH                                               880 (43.4)      120 (48.4)                   1.00                     Ref          67 (50.0)    1.00    Ref              
   AMC                                                625 (30.8)      75 (30.2)                    0.64                     0.47--0.87   53 (39.6)    1.00    0.68--1.47       
   NCC                                                522 (25.8)      53 (21.4)                    1.00                     0.71--1.40   14 (10.4)    0.59    0.32--1.08       
  Education                                                                                        0.322                                                      0.182            
   Less than high school                              513 (25.3)      68 (27.4)                    1.00                     Ref          43 (32.1)    1.00    Ref              
   High school                                        827 (40.8)      109 (44.0)                   1.14                     0.83--1.58   47 (35.1)    0.76    0.49--1.19       
   College or higher                                  664 (32.3)      70 (28.2)                    0.92                     0.64--1.33   41 (31.0)    0.81    0.51--1.31       
   Unknown                                            23 (1.1)        1 (0.4)                      0.36                     0.05--2.60   3 (2.2)      1.65    0.50--5.46       
  Family history of BC                                                                             0.305                                                      0.122            
   No                                                 1,932 (95.3)    232 (93.5)                   1.00                     Ref          130 (97)     1.00    Ref              
   Yes                                                95 (4.7)        16 (6.5)                     1.40                     0.84--2.32   4 (3.0)      0.46    0.15--1.44       
   Unknown                                            0               0                            \-                       \-           0            \-                       
  BMI (kg/m^2^)                                                                                    0.136                                                      0.216            
   \< 18.5                                            55 (2.7)        9 (3.6)                      1.69                     0.86--3.35   6 (4.5)      2.24    0.95--5.26       
   ≥ 18.5, \< 23.0                                    986 (48.6)      114 (46.0)                   1.00                     Ref          54 (40.3)    1.00    Ref              
   ≥ 23.0, \< 25.0                                    505 (24.9)      55 (22.2)                    0.83                     0.60--1.15   32 (23.9)    0.93    0.59--1.45       
   ≥ 25.0                                             462 (22.8)      69 (27.8)                    1.10                     0.81--1.50   36 (26.9)    1.18    0.76--1.82       
   Unknown                                            19 (0.9)        1 (0.4)                      0.41                     0.06--2.96   6 (4.5)      5.33    2.25--12.62      
  TNM stage                                                                                        \< 0.001                                                   \< 0.001         
   0--I                                               893 (44.0)      56 (22.6)                    1.00                     Ref          16 (12.0)    1.00    Ref              
   II                                                 793 (39.1)      103 (41.5)                   1.81                     1.30--2.51   51 (38.1)    2.92    1.66--5.16       
   ≥ III                                              332 (16.4)      89 (35.9)                    4.77                     3.40--6.69   65 (48.5)    11.50   6.61--20.00      
   Unknown                                            9 (0.4)         0                            \-                       \-           2 (1.5)      12.94   2.85--58.66      
  Estrogen receptor                                                                                \< 0.001                                                   \< 0.001         
   Positive                                           1,252 (61.8)    121 (48.8)                   1.00                     Ref          52 (38.8)    1.00    Ref              
   Negative                                           743 (36.7)      124 (50.0)                   1.78                     1.38--2.28   80 (59.7)    2.48    1.74--3.52       
   Unknown                                            32 (0.2)        3 (1.2)                      1.56                     0.49--4.93   2 (1.5)      0.98    0.14--6.94       
  Progesterone receptor                                                                            \< 0.001                                                   \< 0.001         
   Positive                                           1,106 (54.6)    92 (37.1)                    1.00                     Ref          39 (29.1)    1.00    Ref              
   Negative                                           887 (43.8)      153 (61.7)                   2.02                     1.56--2.63   92 (68.7)    2.58    1.76--3.76       
   Unknown                                            34 (1.7)        3 (1.2)                      1.37                     0.43--4.37   3 (2.2)      1.67    0.36--7.71       
  HER2                                                                                             0.388                                                      0.026            
   Positive                                           476 (23.5)      65 (26.2)                    1.00                     Ref          41 (30.6)    1.00    Ref              
   Negative                                           1,288 (63.5)    158 (63.7)                   0.91                     0.68--1.22   79 (59.0)    0.70    0.48--1.02       
   Unknown                                            263 (13.0)      25 (10.1)                    0.74                     0.4--1.18    14 (10.5)    0.68    0.36--1.28       
  Tumor subtype                                                                                    \< 0.001                                                   \< 0.001         
   HR+HER2−                                           1,005 (49.6)    94 (37.9)                    1.00                     Ref          41 (30.6)    1.00    Ref              
   HR+HER2+                                           246 (12.1)      27 (10.9)                    1.11                     0.72--1.70   18 (13.4)    1.67    0.96--2.91       
   HR−HER2+                                           228 (11.2)      38 (15.3)                    1.83                     1.26--2.68   23 (17.2)    2.51    1.50--4.20       
   HR−HER2−                                           281 (13.9)      64 (25.8)                    2.38                     1.73--3.29   38 (28.4)    2.80    1.78--4.39       
   Unknown                                            267 (13.2)      25 (10.1)                    1.04                     0.66--1.62   14 (10.5)    1.38    0.73--2.59       
  Histological grade                                                                               \< 0.001                                                   \< 0.001         
   I                                                  128 (7.2)       8 (3.2)                      1.00                     Ref          2 (1.5)      1.00    Ref              
   II                                                 764 (42.9)      73 (29.4)                    1.10                     0.52--2.30   26 (19.4)    1.13    0.27--4.83       
   III                                                563 (31.6)      139 (56.0)                   1.93                     0.92--4.05   80 (59.7)    2.70    0.64--11.31      
   Unknown                                            324 (18.2)      28 (11.3)                    1.19                     0.54--2.62   26 (19.4)    3.29    0.77--14.09      
  Menopausal                                                                                       0.048                                                      0.150            
   Premenopausal                                      1,288 (63.5)    144 (58.5)                   1.00                     Ref          76 (56.7)    1.00    Ref              
   Postmenopausal                                     724 (35.8)      102 (41.1)                   1.21                     0.84--1.75   56 (41.8)    1.14    0.69--1.89       
   Unknown                                            15 (0.7)        2 (0.8)                      1.34                     0.33--5.45   2 (1.5)      2.69    0.65--11.13      
  Age at menarche (yr)                                                                             0.847                                                      0.198            
   \< 15                                              991 (48.4)      116 (46.8)                   1.00                     Ref          52 (38.8)    1.00    Ref              
   ≥ 15                                               1,008 (49.7)    130 (52.4)                   0.93                     0.72--1.22   79 (59.0)    1.23    0.85--1.79       
   Unknown                                            28 (1.4)        2 (0.8)                      0.50                     0.12--2.02   3 (2.2)      1.73    0.53--5.62       
  Age at menopause among postmenopausal women (yr)                                                 0.092                                                      0.976            
   \< 49                                              282 (39.0)      34 (33.3)                    1.00                     Ref          22 (39.3)    1.00    Ref              
   ≥ 49                                               411 (56.8)      62 (60.8)                    1.34                     0.87--2.07   31 (55.4)    0.86    0.48--1.52       
   Unknown                                            31 (4.3)        6 (5.9)                      1.63                     0.68--3.94   3 (5.4)      1.27    0.38--4.32       
  Parity                                                                                           0.279                                                      0.467            
   Parous                                             179 (8.8)       16 (6.5)                     1.00                     Ref          13 (9.7)     1.00    Ref              
   Nulliparous                                        1,848 (91.2)    232 (93.5)                   1.01                     1.00--1.03   121 (90.3)   1.56    0.88--2.79       
  No. of children among parous women                                                               0.198                                                      0.443            
   1                                                  283 (14.0)      35 (14.1)                    1.00                     Ref          20 (14.9)    1.00    Ref              
   2                                                  1,113 (54.9)    129 (52.2)                   0.97                     0.67--1.41   67 (50.0)    0.88    0.53--1.45       
   ≥3                                                 433 (21.4)      66 (26.6)                    1.22                     0.79--1.89   34 (25.4)    0.98    0.54--1.77       
   Unknown                                            198 (9.8)       2 (0.8)                      1.22                     0.79--1.89   13 (9.7)     \-      \-               
  Duration of breastfeeding among parous women (mo)                                                0.177                                                      0.111            
   Never                                              776 (38.3)      91 (36.7)                    1.00                     Ref          26 (19.4)    1.00    Ref              
   \< 18                                              510 (25.2)      63 (25.4)                    0.79                     0.57--1.10   46 (34.3)    1.89    1.14--3.12       
   ≥ 18                                               552 (27.2)      77 (31.0)                    0.86                     0.62--1.19   49 (36.6)    1.59    0.95--2.66       
   Unknown                                            10 (0.5)        1 (0.4)                      0.75                     0.10--5.40   13 (9.7)     \-      \-               
  Adjuvant chemotherapy                                                                            \< 0.001                                                   \< 0.001         
   Yes                                                1,340 (66.1)    201 (81.0)                   1.00                     Ref          108 (80.6)   1.00    Ref              
   No                                                 383 (18.9)      23 (9.3)                     0.93                     0.57--1.52   9 (6.7)      1.26    0.58--2.73       
   Unknown                                            304 (14.5)      24 (9.7)                     0.89                     0.57--1.39   17 (12.7)    1.30    0.73--2.31       
  Adjuvant hormone therapy                                                                                                                                    \< 0.001         
   Yes                                                1,208 (57.6)    116 (46.8)                   1.00                     Ref          46 (34.3)    1.00    Ref              
   No                                                 378 (18.6)      66 (26.6)                    1.10                     0.72--1.69   34 (25.4)    1.88    1.04--3.41       
   Unknown                                            441 (21.8)      66 (26.6)                    1.11                     0.78--1.57   54 (40.3)    2.29    1.45--3.61       
  Adjuvant radiotherapy                                                                            0.074                                                      0.167            
   Yes                                                1,158 (57.1)    154 (62.1)                   1.00                     Ref          81 (60.5)    1.00    Ref              
   No                                                 473 (23.3)      59 (15.7)                    1.03                     0.74--1.45   29 (21.6)    1.36    0.83--2.25       
   Unknown                                            396 (19.5)      35 (14.1)                    0.83                     0.57--1.21   24 (17.9)    1.11    0.68--1.83       

DFS=disease-free survival; OS=overall survival; CI=confidence interval; SNUH=Seoul National University Hospital; AMC=Asan Medical Center; NCC=National Cancer Center; BC=breast cancer; BMI=body mass index; HER2=human epidermal growth factor receptor 2; HR=hormone receptor.

^\*^*p*-value for log-rank test; ^†^Adjusted for age, TNM stage, and tumor subtype.

###### Extracted single nucleotide polymorphisms in the *HMGB1*-related genes
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  Event       SNP        Chromosome   Gene         Location^\*^   Minor allele   Minor allele frequency
  ----------- ---------- ------------ ------------ -------------- -------------- ------------------------
  DFS         rs243867   16           *MMP2*       Upstream       G              0.4055
  rs243842                            Intronic     C              0.3118         
  OS          rs243842   16           *MMP2*       Intronic       C              0.3118
  rs4145277   13         *HMGB1*      Intronic     T              0.4674         
  rs7656411   4          *TLR2*       Downstream   T              0.4580         
  rs7045953   9          *TLR4*       Downstream   G              0.0994         

*HMGB1*=high mobility group box 1; SNP=single nucleotide polymorphism; DFS=disease-free survival; *MMP2*=matrix metalloproteinase 2; OS=overall survival; *TLR2*=Toll-like receptor 2.

^\*^Location information from University of California, Santa Cruz\'s database.

###### Association between the genetic polymorphisms of *HMGB1*-related genes and breast cancer prognosis
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  Event      Gene        SNP        Additive model   Codominant model                                           
  ---------- ----------- ---------- ---------------- ------------------ ------------ ------- ------ ----- ----- --
  DFS        *MMP2*      rs243867   G                1.26               1.05--1.50   AA      0716   78    Ref   
  GA         978         115        1.09             0.82--1.46                                                 
  GG         333         55         1.62             1.14--2.29                                                 
  rs243842   C           1.24       1.03--1.50       TT                 936          103     Ref                
  CT         893         113        1.16             0.88--1.51                                                 
  CC         180         31         1.63             1.09--2.45                                                 
  OS         *MMP2*      rs243842   C                1.33               1.03--1.71   TT      936    53    Ref   
  CT         893         60         1.16             0.80--1.68                                                 
  CC         180         21         1.93             1.16--3.22                                                 
  *HMGB1*    rs4145277   T          1.29             1.00--1.66         CC           551     33     Ref         
  TC         1,053       66         1.09             0.71--1.66                                                 
  TT         419         35         1.66             1.02--2.70                                                 
  *TLR2*     rs7656411   T          0.76             0.60--0.98         GG           629     50     Ref         
  TG         938         56         0.62             0.42--0.92                                                 
  TT         459         28         0.62             0.39--1.00                                                 
  *TLR4*     rs7045953   G          0.50             0.29--0.84         AA           1,639   119    Ref         
  GA         373         15         0.52             0.30--0.89                                                 
  GG         15          0          \-               \-                                                         

*HMGB1*=high mobility group box 1; SNP=single nucleotide polymorphism; CI=confidence interval; DFS=disease-free survival; *MMP2*=matrix metalloproteinase 2; OS=overall survival; *TLR2*=Toll-like receptor 2.

^\*^Multivariate Cox proportional hazard model adjusted for age, TNM stage, and tumor subtype.

###### Association between polygenetic score and breast cancer prognosis

![](jbc-20-27-i004)

  Event         Group         Total   Event               Hazard ratio (95% CI)^\*^
  ------------- ------------- ------- ------------------- ---------------------------
  DFS           1st tertile   973     110                 Ref
  2nd tertile   441           69      1.34 (0.99--1.82)   
  3rd tertile   348           68      1.72 (1.27--2.34)   
  OS            1st tertile   836     34                  Ref
  2nd tertile   468           38      1.84 (1.15--2.95)   
  3rd tertile   600           62      2.75 (1.79--4.23)   

CI=confidence interval; DFS=disease-free survival; OS=overall survival.

^\*^Multivariate Cox proportional hazard model adjusted for age, TNM stage, and tumor subtype.

[^1]: ^\*^These authors contributed equally to this work.
